Faculty profile

Rob Rottapel

Back to faculty

ProfessorDepartment of Medical BiophysicsUniversity of Toronto

Rob Rottapel

Professor

Department of Medical Biophysics

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
174 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

346

Publications

11,471

Citations

174

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Rethinking ovarian cancer III: the past decade and future directions.
Nature reviews. Cancer · 2026
Figure S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
2026
Supplementary Figure S3 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report
2026

All 346 publications

From the 150 most recent of 346 publications.

Rethinking ovarian cancer III: the past decade and future directions.

Balkwill FR, Laumont CM, Burdett N, Le Saux O, Garsed DW, Grither WR, Nijhuis AM, Recouvreux MS, Kang Z, Zhang R, Chiappinelli KB, Lee JS, Laniti DD, McNeish I, Ahmed AA, Rottapel R, Conejo-Garcia JR, Odunsi K, Pharoah PDP, Zamarin D, Ishak CA, Fotopoulou C, Buckanovich RJ, Labidi-Galy I, Brenton JD, Lengyel E, Cook DP, George SHL, Lheureux S, Drapkin R, Nephew KP, Adams S, Pathania S, Nelson BH, Färkkilä A, Fuh K, Neel BG, Bowtell DD

Nature reviews. Cancer20266 citations

DOI: 10.1038/s41568-026-00916-0 PMID: 41975230

Figure S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion

Charles A. Ishak, Sajid A. Marhon, Naïri Tchrakian, Anjelica Hodgson, Helen Loo Yau, Isabela Martins Gonzaga, Melanie Peralta, Ilinca M. Lungu, Stephanie Gomez, Sheng‐Ben Liang, Shu Yi Shen, Raymond Chen, Jocelyn Chen, Biji Chatterjee, Kevin N. Wanniarachchi, Junwoo Lee, Nicholas Zehrbach, Amir Hosseini, Parinaz Mehdipour, Siyu Sun, Alexander Solovyov, Ilias Ettayebi, Kyle E. Francis, Aobo He, Taiyi Wu, Shengrui Feng, Tiago da Silva Medina, Felipe Campos de Almeida, Jane Bayani, Jason Li, et al. (48 authors)

2026Open Access

DOI: 10.1158/2159-8290.32701405

Supplementary Figure S3 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Nikolina Radulovich, Pamela Soberanis Pina, Molly L. Udaskin, Quan Li, Kevin C. J. Nixon, Irene Y. Xie, Ankita Nand, Joshua C. Rosen, Ming Li, Anjelica Hodgson, Nhu‐An Pham, Amit M. Oza, Mathieu Lupien, Robert K. Rottapel, Ming‐Sound Tsao, Stéphanie Lheureux

2026Open Access

DOI: 10.1158/2767-9764.32705009

Figure 1 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

2026Open Access

DOI: 10.1158/2767-9764.32705048

Supplementary Figure S2 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

2026Open Access

DOI: 10.1158/2767-9764.32705015

Supplementary Figure S10 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

2026Open Access

DOI: 10.1158/2767-9764.32705021

Supplementary Figure S6 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

2026Open Access

DOI: 10.1158/2767-9764.32704991

Table S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion

2026Open Access

DOI: 10.1158/2159-8290.32701372

Table S1 from The FBXO45–GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis

Anagh Anant Sahasrabuddhe, Xiaofei Chen, Kaiyu Ma, Rui Wu, Huan-Chang Liang, Richa Kapoor, Rishi R. Chhipa, Özlem Önder, Courtney McFetridge, John S. Van Arnam, Xiao Zhang, Jennifer J. D. Morrissette, Vinodh Pillai, Marilyn M. Li, Philippe Szankasi, Venkatesha Basrur, Kevin P. Conlon, Tobias D. Raabe, Nathanael G. Bailey, Cory M. Hogaboam, Robert K. Rottapel, Junhyong Kim, Cristina Esquinas López, Matthias Schlesner, Reiner Siebert, Kostiantyn Dreval, Ryan D. Morin, Loredana Moro, Michele Pagano, Louis M. Staudt, et al. (32 authors)

2026Open Access

DOI: 10.1158/2159-8290.32698196

Supplementary Figure S5 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

2026Open Access

DOI: 10.1158/2767-9764.32704997

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Rob Rottapel

Research

Latest papers

Rethinking ovarian cancer III: the past decade and future directions.

Figure S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion

Supplementary Figure S3 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Figure 1 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Supplementary Figure S2 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Supplementary Figure S10 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Supplementary Figure S6 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Table S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion

Table S1 from The FBXO45–GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis

Supplementary Figure S5 from Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report

Frequent collaborators

Robert Rottapel

Jason Moffat

Amit Oza

Stephanie Lheureux

Ming-Sound Tsao

Ming Tsao

Benjamin Neel

Trevor Shepherd

Jeffrey Wrana

Franco Vizeacoumar

Ahmed Aman

Sean Egan

Eldad Zacksenhaus

Catherine O'Brien

Daniel de Carvalho

Sajid Marhon

Mathieu Lupien

Ryan Morin

Marianne Koritzinsky

Bradly Wouters

Anthony Joshua

Patricia Shaw

Rima Al-awar

Mohan Babu